In bioprocessing, many experts talk about the advantages of single-use technology, but making it work requires access to the necessary tools—and lots of them. That’s what MilliporeSigma decided to address with its Mobius® single-use assemblies.

These “assemblies provide flexible, customized single-use solutions to accelerate pharmaceutical drug development and manufacturing,” said company spokesperson Karen Tiano. “This is a critical component in the supply chain for the production of vaccines and medications around the world.”

Instead of buying a collection of parts to get started in single-use, MilliporeSigma’s assembly provides everything a bioprocessor requires: bags, tubing, connectors, and filters, she added.

“These ready-to-use assemblies allow the development and production of products in a wide range of sizes and for a variety of diseases,” Tiano explained.

Plus, MilliporeSigma keeps making more of these assemblies: 1,500 a week a decade ago and now 12,000 a week in the company’s manufacturing facility in Danvers, MA. That adds up to almost 625,000 assemblies in a year. That level of manufacturing reflects the growing demand in the market, continued Tiano.

“We have seen a steady increase in the adoption of this technology by the biopharmaceutical industry,” she said. “The widespread utilization of single-use filter cartridges and capsules paved the way for acceptance of single-use bags and assemblies.”

The application of single-use methods covers the entire lifespan of a therapy.

“It is not uncommon to see new therapies developed using entirely single-use processes—everything from media and buffer preparation to drug-substance transportation and drug-product filling,” Tiano pointed out. “MilliporeSigma’s major technology changes and innovations have been driven by end-user needs, such as to aseptically connect and disconnect single-use systems, automatically monitor, control and collect data from the process and the requirement for more robust, compatible and clean films and components to support critical processing applications.”

A process ends up as more than the sum of the parts, but bioprocessors need the right parts—sometimes assemblies of them—to complete the process.

This site uses Akismet to reduce spam. Learn how your comment data is processed.